The “Coming of Age” of Real‐World Evidence in Drug Development and Regulation

When Are Treatment Blinding and Treatment Standardization Necessary in Real‐World Clinical Trials?

(2021) Jonathan H Watanabe et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?

(2021) Jessica M. Franklin et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

(2021) Eric J Haas et al.   LANCET

Assessing and Interpreting Real‐World Evidence Studies: Introductory Points for New Reviewers

(2021) Shirley V. Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan

(2021) Kinue Nishioka et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Role of Real‐World Evidence in FDA‐Approved New Drug and Biologics License Applications

(2021) Christina A. Purpura et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Integration of Real‐World Data and Genetics to Support Target Identification and Validation

(2021) Jonathan M. Davitte et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

COVID‐19: A Catalyst to Accelerate Global Regulatory Transformation

(2020) Jerry Stewart et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Overcoming Regulatory Aversion to Novel Methods of Evidence Generation

(2019) Elodie Baumfeld Andre et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

80th Anniversary of the discovery of penicillin

(2008) Alasdair Geddes   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS